SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Bellerophon Therapeutics LLC and Its Board of Directors in Connection with Possible Violations of Federal Securities Laws

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky is investigating the Board of Directors of Bellerophon Therapeutics LLC (“Bellerophon” or the “Company”) (NASDAQGM: BLPH) for possible violations of federal securities laws. The investigation concerns whether Bellerophon and certain of its officers and/or directors have violated Section 11 of the Securities Act of 1933 and/or Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On July 27, 2015, Bellerophon reported that its implantable heart device, Bioabsorbable Cardiac Matrix (BCM), failed to prevent heart failure in patients in a large study. On the announcement of this news, the share price of Bellerophon was down $4.72, or approximately 62%, during intraday trading on July 27, 2015, from the prior day’s closing price of $7.65 per share. To obtain additional information, go to:

http://zlk.9nl.com/bellerophon-therapeutics-blph

or contact Joseph E. Levi, Esq. either via email at [e-mail] or by telephone at [phone], toll-free: [phone].

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.